# Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

> **NCT01118598** · PHASE4 · COMPLETED · sponsor: **Hull University Teaching Hospitals NHS Trust** · enrollment: 34 (actual)

## Conditions studied

- Polycystic Ovary Syndrome

## Interventions

- **DRUG:** tredaptive (nicotinic acid/ laropiprant)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01118598
- **Lead sponsor:** Hull University Teaching Hospitals NHS Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118598, "Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01118598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*